{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:02:59Z","timestamp":1769184179835,"version":"3.49.0"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/cad.0b013e32834b72de","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T22:32:56Z","timestamp":1317767576000},"page":"70-80","source":"Crossref","is-referenced-by-count":11,"title":["The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells"],"prefix":"10.1097","volume":"23","author":[{"given":"Marta","family":"\u015awitalska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Nasulewicz-Goldeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Opolska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Maciejewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Kutner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Wietrzyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","article-title":"Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph ALL).","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"R3-8-20210203","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/pr0603708","article-title":"Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance.","volume":"6","author":"Ferrari","year":"2007","journal-title":"J Proteome Res"},{"key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"669","DOI":"10.5858\/2006-130-669-IROAO","article-title":"Imatinib resistance: obstacles and opportunities.","volume":"130","author":"Litzow","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"757","DOI":"10.6004\/jnccn.2005.0045","article-title":"Resistance to imatinib: mechanisms and management.","volume":"3","author":"Deininger","year":"2005","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12185-011-0766-2","article-title":"A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.","volume":"93","author":"Sakai","year":"2011","journal-title":"Int J Hematol"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2002-05-1361","article-title":"BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.","volume":"100","author":"Gorre","year":"2002","journal-title":"Blood"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.leu.2402555","article-title":"Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (GleevecGlivec) in chronic myelogenous leukemia: a translational perspective.","volume":"16","author":"La Rosee","year":"2002","journal-title":"Leukemia"},{"key":"R12-8-20210203","first-page":"188","article-title":"Pharmacologic mitogen-activated proteinextracellular signal-regulated kinase kinasemitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in BcrAbl-expressing human leukemia cells.","volume":"62","author":"Yu","year":"2002","journal-title":"Cancer Res"},{"key":"R13-8-20210203","first-page":"217","article-title":"Molecular pathophysiology of chronic myelogenous leukemia.","volume":"40","author":"Turhan","year":"1998","journal-title":"Hematol Cell Ther"},{"key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1182\/blood.V92.7.2441","article-title":"19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines.","volume":"92","author":"Asou","year":"1998","journal-title":"Blood"},{"key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/excr.1999.4475","article-title":"Role of vitamin D3 receptor in the synergistic differentiation of WEHI-3B leukemia cells by vitamin D3 and retinoic acid.","volume":"249","author":"Li","year":"1999","journal-title":"Exp Cell Res"},{"key":"R16-8-20210203","first-page":"5217","article-title":"Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines.","volume":"19","author":"Opolski","year":"1999","journal-title":"Anticancer Res"},{"key":"R17-8-20210203","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s10637-008-9184-6","article-title":"Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer.","volume":"27","author":"Blanke","year":"2009","journal-title":"Invest New Drugs"},{"key":"R18-8-20210203","doi-asserted-by":"crossref","first-page":"1709S","DOI":"10.1093\/jn\/125.suppl_6.1709S","article-title":"1,25(OH)2D3-regulated human keratinocyte proliferation and differentiation: basic studies and their clinical application.","volume":"125","author":"Bikle","year":"1995","journal-title":"J Nutr"},{"key":"R19-8-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V78.1.75.75","article-title":"Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism.","volume":"78","author":"Zhou","year":"1991","journal-title":"Blood"},{"key":"R20-8-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jcb.240510206","article-title":"Mechanisms of transcriptional activation by steroid hormone receptors.","volume":"51","author":"Baniahmad","year":"1993","journal-title":"J Cell Biochem"},{"key":"R21-8-20210203","first-page":"2644","article-title":"1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1Cip1) in vitro and in vivo.","volume":"59","author":"Hershberger","year":"1999","journal-title":"Cancer Res"},{"key":"R22-8-20210203","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/nar\/gkj460","article-title":"Regulation of the human p21(waf1cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor.","volume":"34","author":"Saramaki","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"R23-8-20210203","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2174\/156802606777864935","article-title":"Vitamin D receptor signaling of monocytic differentiation in human leukemia cells: role of MAPK pathways in transcription factor activation.","volume":"6","author":"Studzinski","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"R24-8-20210203","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jcp.20355","article-title":"Cooperation between antioxidants and 1,25-dihydroxyvitamin D3 in induction of leukemia HL60 cell differentiation through the JNKAP-1Egr-1 pathway.","volume":"204","author":"Wang","year":"2005","journal-title":"J Cell Physiol"},{"key":"R25-8-20210203","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jcp.20731","article-title":"Raf-1 signaling is required for the later stages of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells but is not mediated by the MEKERK module.","volume":"209","author":"Wang","year":"2006","journal-title":"J Cell Physiol"},{"key":"R26-8-20210203","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1038\/sj.onc.1209697","article-title":"Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5-flanking region.","volume":"25","author":"Wang","year":"2006","journal-title":"Oncogene"},{"key":"R27-8-20210203","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.4161\/cc.9.22.13790","article-title":"Inhibition of Cot1Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).","volume":"9","author":"Wang","year":"2010","journal-title":"Cell Cycle"},{"key":"R28-8-20210203","first-page":"235","article-title":"1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors.","volume":"25","author":"Zinser","year":"2005","journal-title":"Anticancer Res"},{"key":"R29-8-20210203","first-page":"2673","article-title":"Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo.","volume":"60","author":"Verlinden","year":"2000","journal-title":"Cancer Res"},{"key":"R30-8-20210203","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/S0968-0896(01)00159-6","article-title":"A non-calcemic sulfone version of the vitamin D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency enhancement of the anticancer drug adriamycin.","volume":"9","author":"Posner","year":"2001","journal-title":"Bioorg Med Chem"},{"key":"R31-8-20210203","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0039-128X(02)00038-7","article-title":"Synthesis and antiproliferative activity of side-chain unsaturated and homologated analogs of 1,25-dihydroxyvitamin D(2). (24E)-(1S)-24-Dehydro-24a-homo-1,25-dihydroxyergocalciferol and congeners.","volume":"67","author":"Chodynski","year":"2002","journal-title":"Steroids"},{"key":"R32-8-20210203","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/CAD.0b013e3280143166","article-title":"Antitumor properties of diastereomeric and geometric analogs of vitamin D3.","volume":"18","author":"Wietrzyk","year":"2007","journal-title":"Anticancer Drugs"},{"key":"R33-8-20210203","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jsbmb.2010.03.017","article-title":"Antitumor properties of (5E,7E) analogs of vitamin D3.","volume":"121","author":"Filip","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R34-8-20210203","doi-asserted-by":"crossref","first-page":"7658","DOI":"10.1016\/j.bmc.2009.09.047","article-title":"Removal of the 20-methyl group from 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD) selectively eliminates bone calcium mobilization activity.","volume":"17","author":"Barycki","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"R35-8-20210203","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.1021\/jm1010447","article-title":"Removal of the 26-methyl group from 19-nor-1alpha,25-dihydroxyvitamin D markedly reduces in vivo calcemic activity without altering in vitro VDR binding, HL-60 cell differentiation, and transcription.","volume":"53","author":"Grzywacz","year":"2010","journal-title":"J Med Chem"},{"key":"R36-8-20210203","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.steroids.2004.05.015","article-title":"Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D3 (PRI-2191).","volume":"69","author":"Wietrzyk","year":"2004","journal-title":"Steroids"},{"key":"R37-8-20210203","first-page":"1925","article-title":"Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D.","volume":"21","author":"Siwinska","year":"2001","journal-title":"Anticancer Res"},{"key":"R38-8-20210203","first-page":"2235","article-title":"Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics.","volume":"25","author":"Pelczynska","year":"2005","journal-title":"Anticancer Res"},{"key":"R39-8-20210203","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2174\/1381612003400407","article-title":"Biological activity in vitro of side-chain modified analogues of calcitriol.","volume":"6","author":"Opolski","year":"2000","journal-title":"Curr Pharm Des"},{"key":"R40-8-20210203","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1432-1033.1981.tb06218.x","article-title":"Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.","volume":"115","author":"Chou","year":"1981","journal-title":"Eur J Biochem"},{"key":"R41-8-20210203","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"R42-8-20210203","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CBC.2009.n.040","article-title":"Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.","volume":"9","author":"Yardley","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"R43-8-20210203","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/JTO.0b013e318200f9ad","article-title":"Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.","volume":"6","author":"Huang","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R46-8-20210203","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","article-title":"A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.","volume":"48","author":"Quintas-Cardama","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"R47-8-20210203","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1179\/102453309X426164","article-title":"Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.","volume":"14","author":"Gucluler","year":"2009","journal-title":"Hematology"},{"key":"R48-8-20210203","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1756-8722-2-21","article-title":"Temozolomide and cisplatin in relapsedrefractory acute leukemia.","volume":"2","author":"Seiter","year":"2009","journal-title":"J Hematol Oncol"},{"key":"R49-8-20210203","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.V77.7.1452.1452","article-title":"Inhibition by 1,25 dihydroxyvitamin D3 of chemically induced erythroid differentiation of K562 leukemia cells.","volume":"77","author":"Moore","year":"1991","journal-title":"Blood"},{"key":"R50-8-20210203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jsbmb.2005.11.004","article-title":"Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells.","volume":"98","author":"Yee","year":"2006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R51-8-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-009-0766-y","article-title":"Treatment of K562 cells with 1,25-dihydroxyvitamin D(3) induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCL(XL), and p21.","volume":"89","author":"Kizildag","year":"2010","journal-title":"Ann Hematol"},{"key":"R52-8-20210203","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/1097-4644(20010315)80:4<471::AID-JCB1001>3.0.CO;2-J","article-title":"Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells.","volume":"80","author":"Wang","year":"2001","journal-title":"J Cell Biochem"},{"key":"R53-8-20210203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00280-007-0666-6","article-title":"Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model.","volume":"62","author":"Wietrzyk","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R54-8-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/stemcells.2004-0117","article-title":"Normal and oncogenic forms of the receptor tyrosine kinase kit.","volume":"23","author":"Lennartsson","year":"2005","journal-title":"Stem Cells"},{"key":"R55-8-20210203","doi-asserted-by":"crossref","first-page":"7765","DOI":"10.1158\/0008-5472.CAN-07-0014","article-title":"Platelet-derived growth factor receptor regulates myeloid and monocytic differentiation of HL-60 cells.","volume":"67","author":"Reiterer","year":"2007","journal-title":"Cancer Res"},{"key":"R56-8-20210203","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.V97.10.3234","article-title":"Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.","volume":"97","author":"Gianni","year":"2001","journal-title":"Blood"},{"key":"R57-8-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0090-4295(02)01591-1","article-title":"Vitamin D receptor: a potential target for intervention.","volume":"60","author":"Johnson","year":"2002","journal-title":"Urology"},{"key":"R58-8-20210203","first-page":"2848","article-title":"Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells.","volume":"51","author":"Cho","year":"1991","journal-title":"Cancer Res"},{"key":"R59-8-20210203","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/ijc.2910570614","article-title":"Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle.","volume":"57","author":"Donaldson","year":"1994","journal-title":"Int J Cancer"},{"key":"R61-8-20210203","first-page":"821","article-title":"Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression.","volume":"1","author":"Hershberger","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"R62-8-20210203","first-page":"421","article-title":"Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo.","volume":"13","author":"Koshizuka","year":"1998","journal-title":"Int J Oncol"},{"key":"R63-8-20210203","first-page":"695","article-title":"1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines.","volume":"5","author":"Moffatt","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"Suppl","key":"R64-8-20210203","first-page":"OL1366","article-title":"Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk MAPK signaling pathway.","volume":"56","author":"Qin","year":"2010","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"R65-8-20210203","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0014-5793(99)00690-0","article-title":"Lack of c-Jun activity increases survival to cisplatin.","volume":"453","author":"Sanchez-Perez","year":"1999","journal-title":"FEBS Lett"},{"key":"R66-8-20210203","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1046\/j.1523-1747.2003.12095.x","article-title":"1alpha,25-dihydroxyvitamin D3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinaseRasMEKextracellular signal regulated kinase 12 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fra1, and c-Jun expression in human keratinocytes.","volume":"120","author":"Johansen","year":"2003","journal-title":"J Invest Dermatol"},{"key":"R67-8-20210203","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.steroids.2004.08.004","article-title":"Side-chain-modified analogs of calcitriol cause resistance of human HL-60 promyelocytic leukemia cells to drug-induced apoptosis.","volume":"70","author":"Chrobak","year":"2005","journal-title":"Steroids"},{"key":"R68-8-20210203","first-page":"281","article-title":"Altered susceptibility of differentiating HL-60 cells to apoptosis induced by antitumor drugs.","volume":"8","author":"Del Bino","year":"1994","journal-title":"Leukemia"},{"key":"R69-8-20210203","first-page":"1817","article-title":"1Alpha,25-dihydroxyvitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase.","volume":"58","author":"Kleuser","year":"1998","journal-title":"Cancer Res"},{"key":"R70-8-20210203","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1006\/excr.1997.3667","article-title":"Antiapoptotic action of 1,25-dihydroxyvitamin D3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c.","volume":"235","author":"Wang","year":"1997","journal-title":"Exp Cell Res"},{"key":"R71-8-20210203","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3727\/096504007783438330","article-title":"The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and s.","volume":"16","author":"Wietrzyk","year":"2007","journal-title":"Oncol Res"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e32834b72de","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:44:58Z","timestamp":1741783498000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201201000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32834b72de","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}